Figure 6.

The roles of m⁶A score in prediction of chemo- and immunotherapeutic benefits of HCC patients in TCGA cohort: (a, b) Somatic mutation landscape of significantly mutated genes across (a) high or (b) low m⁶A score populations. (c, d) The differences in estimated IC50 values between populations. (e) The comparisons in TIDE score between populations. P values were determined with Wilcoxon tests. (f) The proportions of subjects responding to anti-PD-L1therapy in two populations in the IMvigor210 cohort. (g) Kaplan–Meier OS curves for cases with high and low m⁶A scores (log-rank test). (h) The response of cases with high and low m⁶A scores to anti-CTLA-4/PD-1 therapies through SubMap analyses. (i) The comparisons of IPS scores in two populations.